

The Eribulin Story: From Halichondrin B to Halaven ®

Chelsea Harmon


Looper Group

April

Synthesis Club


Halichondrin B

IC₅₀ of 0.0093 ng/mL in B-16 melanoma cell cytotoxicity assay




Halichondrin B

31 Stereocenters




Halichondrin B

2,6,9-trioxatricyclo[3.3.2.0]decane ring system




Halichondrin B

22-Membered Macrocycle




Halichondrin B




Two Spiro-Ketal Formations



Kishi Total Synthesis of Halichondrin B




Kishi Total Synthesis of Halichondrin B




Fragment 1


Kishi Total Synthesis of Halichondrin B




Kishi Total Synthesis of Halichondrin B




Kishi Total Synthesis of Halichondrin B






Kishi Total Synthesis of Halichondrin B




Kishi Total Synthesis of Halichondrin B




1. 
pyr. CH₂Cl₂
2. TBSOTf, Et₃N, CH₂Cl₂, 93%
3. K₂CO₃, MeOH, 93%
4. DMP



Kishi Total Synthesis of Halichondrin B




Discovery of the Eastern Fragment's Activity




Compound	DLD-1 IC ₅₀ , nM	U937 IC ₉₉ , 0h, nM	U937 IC ₉₉ , 10h, nM	Reversibility Ratio	Fold Resistance
HB	0.74 ± 0.03	8	25	3	2.8
1	3.4 ± 0.40	9	220	24	12
2	1.8 ± 0.00	10	300	30	10
3	0.67 ± 0.09	2	15	8	6.2
4	13.0 ± 0.20	10	10	1	15


First Generation Process Synthesis of Eribulin Mesylate by Eisai




First Generation Process Synthesis of Eribulin Mesylate by Eisai




First Generation Process Synthesis of Eribulin Mesylate by Eisai




First Generation Process Synthesis of Eribulin Mesylate by Eisai




First Generation Process Synthesis of Eribulin Mesylate by Eisai




Deuterium Studies



First Generation Process Synthesis of Eribulin Mesylate by Eisai



Summary



Questions?